sten andreasson

Prof. sten andreasson


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2017 in Genes
Verified
Journal Article
Open access
PDF file
ATAnna Tracewska-Siemiątkowska
Anna Tracewska-Siemiątkowska
LHLonneke Haer-Wigman
Lonneke Haer-Wigman
DBDanielle G. M. Bosch
Danielle G. M. Bosch
DNDeborah Nickerson
Deborah Nickerson
MBMichael J. Bamshad
Michael J. Bamshad
LTLisbeth Tranebjærg
Lisbeth Tranebjærg
Whole exome sequence analysis was performed in a Swedish mother–father-affected proband trio with a phenotype characterized by progressive retinal degeneration with congenital nystagmus, profound congenital hearing impairment, primary amenorrhea, agenesis of the corpus callosum, and liver disease. A homozygous variant c.806T > C, p.(F269S) in the tyrosyl-tRNA synthetase gene (YARS) was the only identified candidate variant consistent with autosomal recessive inheritance. Mutations in YARS have previously been associated with both autosomal dominant Charcot-Marie-Tooth syndrome and a recently reported autosomal recessive multiorgan disease. Herein, we propose that mutations in YARS underlie another clinical phenotype adding a second variant of the disease, including retinitis pigmentosa and deafness, to the spectrum of YARS-associated disorders.

2 May 2014 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
SAsten andreasson
sten andreasson
FGFredrik Ghosh
Fredrik Ghosh

8 July 2023 in Genes
Verified
Journal Article
Open access
PDF file
MAMaria Areblom
Maria Areblom
SKSten Kjellström
Sten Kjellström
SAsten andreasson
sten andreasson
AÖAnders Öhberg
Anders Öhberg
LGLotta Gränse
Lotta Gränse
UKUlrika Kjellström
Ulrika Kjellström
In the present era of evolving gene-based therapies for inherited retinal dystrophies (IRDs), it has become increasingly important to verify the genotype in every case, to identify all subjects eligible for treatment. Moreover, combined insight concerning phenotypes and genotypes is crucial for improved understanding of thevisual impairment, prognosis, and inheritance. The objective of this study was to investigate to what extent renewed comprehensive genetic testing of patients diagnosed with IRD but with previously inconclusive DNA test results can verify the genotype, if confirmation of the genotype has an impact on the understanding of the clinical picture, and, to describe the genetic spectrum encountered in a Swedish IRD cohort. The study included 279 patients from the retinitis pigmentosa research registry (comprising diagnosis within the whole IRD spectrum), hosted at the Department of Ophthalmology, Skåne University hospital, Sweden. The phenotypes had already been evaluated with electrophysiology and other clinical tests, e.g., visual acuity, Goldmann perimetry, and fundus imaging at the first visit, sometime between 1988–2015 and the previous—in many cases, multiple—genetic testing, performed between 1995 and 2020 had been inconclusive. All patients were aged 0–25 years at the time of their first visit. Renewed genetic testing was performed using a next generation sequencing (NGS) IRD panel including 322 genes (Blueprint Genetics). Class 5 and 4 variants, according to ACMG guidelines, were considered pathogenic. Of the 279 samples tested, a confirmed genotype was determined in 182 (65%). The cohort was genetically heterogenous, including 65 different genes. The most prevailing were ABCA4 (16.5%), RPGR (6%), CEP290 (6%), and RS1 (5.5%). Other prevalent genes were CACNA1F (3%), PROM1 (3%), CHM (3%), and NYX (3%). In 7% of the patients there was a discrepancy between the diagnosis made based on phenotypical or genotypical findings alone. To conclude, repeated DNA-analysis was beneficial also in previously tested patients and improved our ability to verify the genotype–phenotype association increasing the understanding of how visual impairment manifests, prognosis, and the inheritance pattern. Moreover, repeated testing using a widely available method could identify additional patients eligible for future gene-based therapies.

30 March 2006 in Acta Ophthalmologica Scandinavica
Verified
Journal Article
Closed access
PDF file
SAsten andreasson
sten andreasson

23 November 2016 in Acta Ophthalmologica
Verified
Journal Article
Open access
PDF file
CKChristina Kamme
Christina Kamme
AMAnja Kathrin Mayer
Anja Kathrin Mayer
TSTim M. Strom
Tim M. Strom
SAsten andreasson
sten andreasson
NWNicole Weisschuh
Nicole Weisschuh

1 March 2014 in JAMA Ophthalmology
Verified
Journal Article
Open access
PDF file
SKSten Kjellström
Sten Kjellström
FGFredrik Ghosh
Fredrik Ghosh
CVCamasamudram Vijayasarathy
Camasamudram Vijayasarathy
SAsten andreasson
sten andreasson
Retinoschisin (RS1), the product of RS1 located on the X chromosome, is expressed mainly in retina.1 The 24-kDa RS1 encodes a highly conserved sequence motif termed the discoidin domain, which is a critical determinant of the structural and functional integrity of the retina.2 Mutations in RS1 that lead to either complete loss of RS1 expression or its accumulation as a nonfunctional misfolded form are the underlying causes of X-linked retinoschisis (XLRS).3 This disorder, seen exclusively in young males, is characterized by splitting, or schisis, affecting all retinal layers. The precise molecular mechanism by which RS1 functions is still undefined. During development, there is a wave of RS1 expression beginning at the retinal surface and spreading progressively in more distal retinal layers as they differentiate.4 In adult mice, RS1 is expressed in all retinal neurons except horizontal cells,4 with a predominance in photoreceptor inner segments and bipolar cells.